Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
CJC-1295 5 mg + Ipamorelin 5 mg is a dual-peptide research blend designed for advanced studies related to growth hormone signaling, IGF-1 pathway modulation, recovery-related biology, sleep-associated endocrine activity, body composition models, and metabolic regulation research.
This formulation combines two widely studied secretagogue-based peptide systems:
CJC-1295 is a synthetic peptide analog associated with growth hormone-releasing hormone (GHRH) research, commonly investigated for its role in stimulating endogenous growth hormone signaling through GHRH receptor pathways and supporting IGF-1-related research models.
Ipamorelin is a selective peptide secretagogue commonly studied for its interaction with ghrelin receptor / growth hormone secretagogue receptor (GHS-R) pathways, with research interest focused on pulsatile growth hormone signaling, recovery-related endocrine activity, and metabolic support models.
Together, CJC-1295 + Ipamorelin are commonly investigated as a complementary endocrine research system due to their potential involvement in:
endogenous growth hormone signaling
IGF-1-associated pathways
recovery and regenerative research models
body composition and metabolic regulation
sleep-related endocrine activity
lean mass and tissue recovery research
performance and resilience models
hormonal rhythm and secretagogue-based signaling
Synthera Labs presents this compound as part of its endocrine and recovery research line, supported by global raw material sourcing, analytical documentation review, downstream processing standards, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide blend
Concentration: 5 mg CJC-1295 + 5 mg Ipamorelin
Total content: 10 mg
Category: Endocrine / Recovery Research
Peptide system: CJC-1295 + Ipamorelin
Use: Research use only
CJC-1295 5 mg + Ipamorelin 5 mg is a dual-peptide research blend designed for advanced studies related to growth hormone signaling, IGF-1 pathway modulation, recovery-related biology, sleep-associated endocrine activity, body composition models, and metabolic regulation research.
This formulation combines two widely studied secretagogue-based peptide systems:
CJC-1295 is a synthetic peptide analog associated with growth hormone-releasing hormone (GHRH) research, commonly investigated for its role in stimulating endogenous growth hormone signaling through GHRH receptor pathways and supporting IGF-1-related research models.
Ipamorelin is a selective peptide secretagogue commonly studied for its interaction with ghrelin receptor / growth hormone secretagogue receptor (GHS-R) pathways, with research interest focused on pulsatile growth hormone signaling, recovery-related endocrine activity, and metabolic support models.
Together, CJC-1295 + Ipamorelin are commonly investigated as a complementary endocrine research system due to their potential involvement in:
endogenous growth hormone signaling
IGF-1-associated pathways
recovery and regenerative research models
body composition and metabolic regulation
sleep-related endocrine activity
lean mass and tissue recovery research
performance and resilience models
hormonal rhythm and secretagogue-based signaling
Synthera Labs presents this compound as part of its endocrine and recovery research line, supported by global raw material sourcing, analytical documentation review, downstream processing standards, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide blend
Concentration: 5 mg CJC-1295 + 5 mg Ipamorelin
Total content: 10 mg
Category: Endocrine / Recovery Research
Peptide system: CJC-1295 + Ipamorelin
Use: Research use only